Advancing precision oncology requires effective biomarker testing and actionable insights that drive better patient outcomes. With next-generation sequencing (NGS) testing in your hospital, you can get the insights you need when you need them - in days, not weeks.
Extensive tools menu spans all stages of drug development
>600 labs in across the world rely on our technology
CDx approvals in multiple countries and continents
In oncology clinical research, a single solution can never fit all the different interactions, samples, and tumors to be tested.
That's why we equip you with a whole spectrum of solutions for tumor profiling from FFPE tissue samples to liquid biopsy.
Our streamlined end-to-end workflows, relevant test menus, and support are empowering laboratories around the world to adopt NGS and move precision oncology forward.
Oncomine Dx Target Test was approved by the FDA in 2017, followed by self-declaration and launch of a CE marked version in Europe and approval in South Korea in 2018, and by MHLW in Japan in 2019.